Losartan in Cushing's syndrome

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 20, Issue 2, 1998, Pages 163-168

  Zacharieva, S ^a   Orbetzova, M ^a   Natchev, E ^a   Vergilova, J ^a   Andrewa, M ^a   Wipperrnann, M ^b   Torbova, S ^c   Tzingilev, D ^d   Angelova Gateva, P ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b Nichols Institute Diagnostics   (Netherlands)

^c Cardiovasc Cent   (Bulgaria)

^d National Oncology Center Bulgaria   (Bulgaria)

Author keywords

Active renin; Cushing's syndrome; Kallikrein; Losartan

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; LOSARTAN;

ARTICLE; CLINICAL TRIAL; CUSHING SYNDROME; DRUG EFFECT; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM INTAKE;

ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; CUSHING SYNDROME; HUMANS; HYPERTENSION; KALLIKREIN-KININ SYSTEM; KALLIKREINS; LOSARTAN; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0031922005     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.1998.20.2.472459     Document Type: Article

References (35)

1. Krakoff, L.R., Elijovich, F. Cushing's syndrome and exogenous glucocorlicoid hypertension. Clin Endocrinol Metab 1981, 10:479-88.
2. Christy, N.P., Laragh, J.H. Pathogenesis of hypokalemic alkalosis in Cushing's syndrome. New Engl J Med 1961, 265: 1083-8.
3. Schambelan, M., Slaton Jr. P.E., Biglieri, E.G. Mineralocorticoid production in hyperadrenocorticism. Am J Med 1971, 51: 299-303.
4. Elijovich, F., Krakoff, L.R. Effect of converting enzyme inhibition on glucocorticoid hypertension in the rat. Am J Physiol 1980, 238.
5. Handa, M., Kondo, K., Suzuki, H., Saruta, T. Urinary prostaglandin E2 and kallikrein excretion in glucocorticoid hypertension in rats. Clin Sci 1983, 65: 37-42.
6. Saruta, T., Suzuki, H., Handa, M., Igarashi, Y., Kondo, K., Senba, S. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab 1986, 62: 275-9.
7. Imura, O., Shimamoto, K. Role of kallikrein-kinin system in the hypotensive mechanisms of converting enzyme inhibitors in essential hypertension. J Cardiovasc Pharmacol 1989, 13 (Suppl. 3) S63-6.
8. Zacharieva, S., Torbova, S., Orbetzova, M., Borissova, A.-M., Andonova, K. Effects of perindopril treatment on plasma and urine kallikrein activity and the stable metabolite of prostaglandin E2 in patients with essential hypertension. Meth Find Exp Clin Pharmacol 1996, 18: 205-9.
9. Smith, R.D., Chiu, A.T., Wong, P.C., Herblin, W.F., Timmermans, P.B.M.W.M. Pharmacology of nonpeptide angiotensin II receptor antagonists. Annu Rev Pharmacol Toxicol 1992, 32: 135-65.
10. Campbell, D.J., Kladis, A., Valentijn, A.J. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol 1995, 26: 233-40.
11. Amundsen, E., Putter, J., Friberger, P., Knos, M., Larsbraten, M., Claeson, G. Method for determination of glandular kallikrein by means of a chromogenic tripeptide substrate. Adv Exp Med Biol 1979, 120A: 83-95.
12. Orbetzova, M., Zacharieva, S., Angelova-Gateva, P., Mucha, I., Andonova, K. Effects of indomethacin and meclofenamate on kallikrein activity and a stable metabolise of prostaglandin E2 in healthy subjects. Endocrinol Metab 1995, 2: 33-7.
13. Crane, M.G., Harris, J.J. Deoxycorticosterone secretion rates in hyperadrenocorticism. J Clin Endocrinol 1966, 26: 1135-43.
14. Hogan, M.J., Schambelan, M., Biglieri, E.G. Concurrent hypercortisolism and mineralocorticoidism. Am J Med 1977, 62: 777-82.
15. Cassar, J., Loizou, S., Kelly, W.F., Mashiter, K., Joplin, G.F. Deoxycorticosterone and aldosterone excretion in Cushing's syndrome. Metabolism 1980, 29: 115-20.
16. Hermus, A., Hobma, S., Pieters, G., van de Calseyde, J., Smals, A., Kloppenborg, P. Are the hypokalemia and hypertension in Cushing's disease caused by apparent mineralocorticoid excess? Horm Metab Res 1991, 23: 572-3.
17. Haynes, F.W., Forsham, P.M., Hume, D.M. Effects of ACTH, cortisone, desoxycorticosterone and epinephrine on plasma hypertensinogen and renin concentration of dogs. Am J Physiol 1953, 172: 265-9.
18. Krakoff, L.R. Measurement of plasma renin substrate by RIA of angiotensin I: Concentration in syndromes associated with steroid excess. J Clin Endocrinol Metab 1973, 37: 110-1.
19. Krakoff, L., Nicolis G., Amsel, B. Pathogenesis of hypertension in Cushing's syndrome. Am J Med 1975, 58: 216-20.
20. Bricaire, H., Thibonnier, M., Hautecouverture, M., Corvol, P., Luton, J-P. Variations du système renine angiotensine aldosterone dans la maladie de Cushing. Nouv Press Med 1980, 9: 1007-9.
21. Ganguiy, A., Weinberger, M.H., Grim, C.E. The renin-angiotensin-aldosterone system in Cushing's syndrome and pheochromocytoma. Horm Res 1983, 17: 1-10.
22. Ritchie, C.M., Sheridan, B., Fraser, R. et al. Studies on the pathogenesis of hypertension in Cashing's disease and acromegaly. Q J Med 1990, 76: 855-67.
23. Jasuda, G., Shionoiri, H., Umemura, S., Takasaki, I., Ishii, M. Exaggerated blood pressure response to angiotensin II in patients with Cushing's syndrome due to adrenocortical adenoma. Eur J Endocrinol 1994, 131: 582-8.
24. Zacharieva, S., Stoeva, I., Matrozov, P., Andonova, K. Plasma aldosterone response to metoclopramide in patients with Cushing's disease. Exp Clin Endocrinol 1993, 101: 138-43.
25. Vetter, W., Vetter, H., Beckershoff, R., Redlich, B., Cottier, P., Siegenthaler, W. The effect of saralasin (I-sar-8-ala-angiotensin II), on blood pressure in patients with Cushing's syndrome. Klin Wochenschr 1976, 54: 661-3.
26. Hollenberg, N.K., Williams, G.H., Burger, B., Ishikawa, I., Adams, D.F. Blockade and stimulation of renal, adrenal and vascular angiotensin II receptors with I-sar, 8-ala angiotensin II in normal man. J Clin Invest 1976, 57: 39-46.
27. Greminger, P., Vetter, W., Groth, H., Luscher, T., Tenschert, W., Siegenthaler, W., Vetter, H. Captopril in Cushing's syndrome. Klin Wochenschr 1984, 62: 855-8.
28. Bonner, G., Autenrieth, R., Marin-Grez, M., Stocker, M., Berecek, K., Gross, F. Changes in urinary kallikrein activity in steroid induced hypertension. In: Serono Symposium No 50, Endocrinology of Hypertension. Mantero, F., Biglieri, E.G., Edwards, C.R.W. (Eds.). Academic Press: London 1982, 307-13.
29. Siragy, H.M., Ibrahim, M.M., Jaffa, AA. Mayfield, R., Margolius, H.S. Rat renal interstitial bradykinin prostaglandin E2, and cyclic 3′,5′-monophosphate: Effects of altered sodium intake. Hypertension 1994, 23: 1068-70.
30. Mac Farlane, N.A.A., Mills, I.H., Wraight, E.P. Changes in kallikrein excretion during arterial infusion of angiotensin. J Endocrinol 1974, 61: 72P.
31. Gardes, J., Baussant, T., Corvol, P., Menard, J., Alenc-Gelas, F. Effect of bradykinin and kininogens in isolated rat kidney vasoconstricted by angiotensin II. Am J Physiol 1990, 258: F1273-81.
32. Geller, R.G., Margolius, H.S., Pisano, J.J., Keiser, H.R. Effects of mineralocorticoids, altered sodium intake, and adrenaletomy on urinary kallikrein in rats. Cric Res 1972, 31: 857-61.
33. Grossman, E., Peleg, E., Carroll, J., Shamiss, A., Rosenthal, T. Hemodynamic and humoral effects of the angiotensin II antagonist Insartan in essential hypertension. Am J Hypertens 1994, 7: 1041-4.
34. Goldberg, M.R., Bradstreet,T.E., McWilliams, E.J. et al. Biochemical effects of losartan, a non-peptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995, 25: 37-46.
35. Misumi, J., Alhenc-Gelas, F., Marre, M., Marchetti, J., Corvol, P., Menard, J. Regulation of kallikrein and renin release by the isolated perfused rat kidney. Kidney Int 1983, 24: 58-65.